Greenwich LifeSciences, Inc. business relationships
Companies named in Greenwich LifeSciences, Inc.’s 10-K filed 2026-06-01, and public companies whose annual reports name Greenwich LifeSciences, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.2 / 10
- AI naming
- <1 / 100 Top 13% in its category
- Agent readiness
- 25 / 100
- AI adoption
- 0 / 100
Layers: Peptides
Named in Greenwich LifeSciences, Inc.’s annual report 3
“or biosimilar) alone or in combination with Perjeta (pertuzumab), both manufactured and marketed by Roche/Genentech, may currently only” SEC filing
“We have not entered into a supply agreement with the manufacturer for GM-CSF, and instead” SEC filing
“or biosimilar) alone or in combination with Perjeta (pertuzumab), both manufactured and marketed by Roche/Genentech, may currently only” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.